Relay Therapeutics, Inc.
RLAY
$3.26
$0.061.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -15.91% | -16.71% | |||
| Gross Profit | 15.91% | 16.71% | |||
| SG&A Expenses | 4.06% | -1.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.82% | -14.06% | |||
| Operating Income | 11.82% | 14.06% | |||
| Income Before Tax | 13.73% | 4.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.73% | 4.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.73% | 4.45% | |||
| EBIT | 11.82% | 14.06% | |||
| EBITDA | 11.95% | 14.23% | |||
| EPS Basic | 27.71% | 9.51% | |||
| Normalized Basic EPS | 27.71% | 19.43% | |||
| EPS Diluted | 27.71% | 9.51% | |||
| Normalized Diluted EPS | 27.71% | 19.43% | |||
| Average Basic Shares Outstanding | 19.33% | 5.58% | |||
| Average Diluted Shares Outstanding | 19.33% | 5.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||